XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Unrestricted cash and cash equivalents $ 384,984 $ 409,660
Restricted cash and cash equivalents 48,208 96,968
Loans, interest and fees receivable, at fair value 1,817,976 1,026,424
Loans, interest and fees receivable, gross 105,267 470,293
Allowances for uncollectible loans, interest and fees receivable 1,643 57,201
Deferred revenue 16,190 29,281
Notes payable, at face value $ 1,653,306 $ 1,278,864
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,453,415 14,804,408
Common stock, outstanding (in shares) 14,453,415 14,804,408
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,204,640 3,188,533
Preferred stock, shares outstanding (in shares) 3,204,640 3,188,533
Preferred stock, liquidation preference $ 80,100 $ 80,100
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 202,200 209,500
Restricted cash and cash equivalents 27,600 75,900
Loans, interest and fees receivable, at fair value 1,735,900 925,500
Loans, interest and fees receivable, gross 0 369,600
Allowances for uncollectible loans, interest and fees receivable 0 55,100
Deferred revenue 0 8,200
Notes payable, at face value $ 1,586,000 $ 1,223,400